A dimly lit data centre corridor lined with illuminated server racks, a lone figure in silhouette standing among them.

July was a month about ownership. Not compliance, not litigation skill – ownership. Google’s edge sits on TPU technology that competitors must come back and license. Sanofi lost the mRNA product...

Appraiser seen from behind writing in a ledger beside an old hardcover book in a bright library workroom.

What happens when intellectual property built into your products turns out to belong to someone else? This week supplied three expensive answers. Each involved one of the world’s most powerful companies...

Brass chess knight on a dark reflective surface over a faint glowing world-map grid, shallow focus.

Over the past two decades, US firm value flipped from mostly tangible to over 90% intangible — and the rulebook for defending those intangibles quietly rewrote itself underneath everyone. A recent...

An engineer in a hi-vis vest looks down from a walkway at the lit concrete foundations of a construction site at dusk.

The most valuable intellectual property in your business is often not the product your customers see — it’s the platform underneath it: the data it learned from, the delivery technology it...

Close-up of a partly assembled watch movement with brass gears and tweezers on a dark wooden workbench in warm light.

What actually decides an IP dispute — the strength of your rights, or the machinery around them? This past week delivered three very different answers to that question, and each one...

Open glass vault door in a modern room with light and glowing particles flowing out toward a window. (108 characters)

The most valuable lesson in intellectual property this week wasn’t a single ruling — it was a pattern. Across a landmark licensing deal, a patent that collapsed over one character, and...

Engineer walking away with a glowing document of patent drawings, leaving a blue-lit laser clean room behind.

A former engineer leaves, starts a company, and files a patent. Months later the original employer discovers the application describes technology that looks remarkably like a project the engineer worked on...

Two race cars labeled Brand Name Pharma and Generic Competition racing on track near a sign reading Patent Expiration Ahead and a cliff labeled The Drug Patent Cliff

IP Organiser’s recently compiled record of every pharmaceutical patent term extension granted in Australia maps roughly 1,600 extended patents across 850 products, and the patterns are worth reading closely. Activity is...

Business professionals discussing legal risk and defensive tactics around a conference table

Amending the basis of your validity challenge in patent litigation is never just a procedural move — it is a strategic play with real commercial consequences. What stands out in AstraZeneca...